D.E. Shaw & Co’s Kymera Therapeutics KYMR Stock Holding History

D.E. Shaw & Co’s Portfolio KYMR Stock Details KYMR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$321K	Buy	+2,800	New	+$241K	﹤0.01%	4385
2025 Q1	–	Sell	-82,578	Closed	-$3.32M	–	4512
2024 Q4	$3.32M	Sell	82,578 -105,619	-56%	-$4.77M	﹤0.01%	2313
2024 Q3	$8.91M	Sell	188,197 -107,375	-36%	-$4.74M	0.01%	1498
2024 Q2	$8.82M	Buy	295,572 +227,810	+336%	+$7.89M	0.01%	1410
2024 Q1	$2.72M	Buy	+67,762	New	+$2.42M	﹤0.01%	2388
2023 Q2	–	Sell	-27,032	Closed	-$801K	–	4396
2023 Q1	$801K	Buy	27,032 +13,553	+101%	+$437K	﹤0.01%	3307
2022 Q4	$336K	Buy	13,479 +2,662	+25%	+$71K	﹤0.01%	4042
2022 Q3	$235K	Buy	+10,817	New	+$285K	﹤0.01%	4406
2021 Q2	–	Sell	-14,645	Closed	-$569K	–	4889
2021 Q1	$569K	Sell	14,645 -16,947	-54%	-$1.02M	﹤0.01%	3449
2020 Q4	$1.96M	Buy	+31,592	New	+$1.54M	﹤0.01%	2569

Other funds holding KYMR

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

D.E. Shaw & Co's KYMR Position: Q2 2026 in Review

D.E. Shaw & Co opened a new position in Kymera Therapeutics (KYMR) in Q2 2026: 2,800 shares worth $321K. The stake represents ﹤0.01% of the portfolio and ranks #4385 among its holdings. This is a return to the name: D.E. Shaw & Co previously reported a position in KYMR as recently as Q4 2024.

D.E. Shaw & Co first reported a position in KYMR in Q4 2020 and has held it in 10 quarters since. The position peaked at $8.91M in Q3 2024. 277 funds tracked by Wall St. Rank hold KYMR as of Q2 2026.

D.E. Shaw & Co held 2,800 shares of Kymera Therapeutics worth $321K as of Q2 2026.
Kymera Therapeutics was a new D.E. Shaw & Co position in Q2 2026.
Kymera Therapeutics made up ﹤0.01% of D.E. Shaw & Co's portfolio in Q2 2026, its #4385 holding.
D.E. Shaw & Co first reported a position in Kymera Therapeutics in Q4 2020 and has held it in 10 quarters since.
D.E. Shaw & Co's Kymera Therapeutics position peaked at $8.91M in Q3 2024.
277 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.